Product Description
Boston Pharma is developing bos-589, an Oral TK Inhibitor for Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03977155)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boston Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Irritable Bowel Syndrome|Diarrhea
Phase 1: Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BOS-589-201 | P2 |
Completed |
Irritable Bowel Syndrome|Diarrhea |
2020-05-06 |
|
| NCT03154086 | P1 |
Completed |
Irritable Bowel Syndrome |
2018-03-05 |